Navigation Links
Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
Date:6/24/2013

d additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy.

More information is available at www.sorrentotherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the clinical trial results from third parties, and the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additio
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market
2. Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017
3. North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017
4. Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission
5. Mast Therapeutics Prices Public Offering Of Units
6. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
7. PTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer
8. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
9. Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
10. Cell Therapeutics to Present at Upcoming Investor Conferences
11. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
(Date:11/18/2014)... 18, 2014 Array Architects is proud ... expertise to the nation's hospitals and health systems. It ... those dedicating their careers to the advancement of both ... in her respective field, Laura Silvoy has been chosen ... 2014 Winter Simulation Conference. , Laura will present ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Fourth Quarter Highlights:, -- Record revenues of $82.0 million, up 22% from the prior year,s fourth ... quarter ... $0.23, a 130% increase over last year,s ... of $24.3 million, revolving debt facility paid off, -- Launch of four new food and beverage products and ...
... WILMINGTON, N.C., Dec. 12 PPD, Inc. ... M.D., as director,of strategic development, to lead the ... Dr. Mathew will provide strategic leadership for PPD,s ... project management,and patient recruitment for key therapeutic areas. ...
... 12 Beckman Coulter,Inc. (NYSE: BEC ), ... complex biomedical testing, announced today that Susan R.,Nowakowski, ... Services, Inc. (NYSE: AHS ) has been ... effective December 10., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2007 Financial Results 2Martek Announces Fourth Quarter and FY 2007 Financial Results 3Martek Announces Fourth Quarter and FY 2007 Financial Results 4Martek Announces Fourth Quarter and FY 2007 Financial Results 5Martek Announces Fourth Quarter and FY 2007 Financial Results 6Martek Announces Fourth Quarter and FY 2007 Financial Results 7Martek Announces Fourth Quarter and FY 2007 Financial Results 8Martek Announces Fourth Quarter and FY 2007 Financial Results 9Martek Announces Fourth Quarter and FY 2007 Financial Results 10Martek Announces Fourth Quarter and FY 2007 Financial Results 11Martek Announces Fourth Quarter and FY 2007 Financial Results 12Martek Announces Fourth Quarter and FY 2007 Financial Results 13Martek Announces Fourth Quarter and FY 2007 Financial Results 14Martek Announces Fourth Quarter and FY 2007 Financial Results 15Mathew to Lead PPD Drug Development Operations and Expansion in India 2Mathew to Lead PPD Drug Development Operations and Expansion in India 3Beckman Coulter Elects AMN Healthcare Executive to Board of Directors 2
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... to put a flashlight up to our palms to ... in St. Louis engineers are using a similar idea ... imaging of cancerous tissues and to develop potential treatments. ... Distinguished Professor of Biomedical Engineering at the School of ... technology that allows researchers to better focus light in ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... KAN. -- It,s a cloak that surpasses all others: ... change the way bacteria and other cells are imaged. ... Kansas State University, and his research team are wrapping ... bacteria under electron microscopes. Berry,s method creates a carbon ...
... 15In the latest twist on optical knots, New York ... create extended and knotted optical traps in three dimensions. ... Optical Society,s (OSA) open-access journal Optics Express , ... intensity traces out a knotted trajectory in space, for ...
... variety of plant seedlings suffer most from competition when planted ... relatives in field soils, researchers from Case Western Reserve University ... when seeds of the same species are buried among relatives ... and grow better early in life in close relatives, habitats ...
Cached Biology News:All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 2All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 3Tying the knot with computer-generated holograms: Winding optical path moves matter 2Tying the knot with computer-generated holograms: Winding optical path moves matter 3Seedlings thrive with distant relatives, seeds with close family 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Biology Products: